

REMARKS/ARGUMENTS**Claims**Claims 4 - 6 and 21

Applicants acknowledge the Examiner's allowance of claims 4 – 6 and 21.

35 U.S.C. § 112 ¶ 1 Paragraph Rejection of Claims 23 - 26

The Office Action rejected Claims 23 - 26 under 35 U.S.C. § 112 ¶ 1 as failing to comply with the written description requirement. The Office Actions states: “applicant has amended claim 23 to include ‘treatment of prostate cancer or uterine cervical cancer’ but applicant has no support for the addition of uterine cervical cancer. Applicant mentions treatment of cervical cancer and mentions treatment of uterine cancer ....”.

Applicants have amended Claim 23 to more clearly claim a method of treatment for prostate cancer and cervical cancer. Applicants acknowledge the Examiner's observation that the specification gives support for prostate cancer and cervical cancer.

The Office Action also states: “applicant has not provided any direction towards treatment of uterine cancer or treatment of cervical cancer or treatment of uterine cervical cancer.”

Applicants disagree with the conclusion of the Examiner and Traverse.

Experimental Example 1 (Page 104 – 105 of Specification) describes the inhibiting effect of the compounds disclosed in Examples 1 to 108 with nuclear extracts of HeLa cells as the HDAC source (emphasis added). HeLa cells are from a well-known and commonly used immortal cell line derived from cervical cancer cells taken from a woman named Henrietta Lacks. Hela cells are model cells used to test compounds on a wide range of cancers.

The treatment of prostate cancer and cervical cancer with the disclosed compounds is described at Page 24, paragraph 5, line 3 to Page 25, paragraph 1, line 2 of the Specification.

The Examiner is requested to withdraw the 35 U.S.C. § 112 ¶ 1 Rejection. In light of the foregoing arguments and amendments to the claims, the Examiner is respectfully requested to allow Claims 23 - 26.

No Disclaimers or Disavowals

Although the present communication may include alterations to the claims, the Applicants are not conceding in this application that previously pending claims are not patentable. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. The Applicants reserve the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that the Applicants have made any disclaimers or disavowals of any subject matter supported by the present application.

**Remarks**

Claims 4 – 6, 21, 23 – 26 are pending. Claim 23 is Currently amended. Claims 4 - 6, 21 and 24 - 26 are Previously presented. Claims 1 – 3, 7 – 20, 22, 27 and 28 are Canceled.

Applicants respectfully request the entrance of the amendments. No New Matter was entered with these amendments.

No fees are believed due; however, the Commissioner is authorized to charge any additional fees now and in the future which may be due, including any fees for additional extension of time, or credit overpayment to credit card information.

Date: October 17, 2009

/KOH/  
Kirk Hahn  
Agent of Record  
Registration No. 51,763  
Customer Number 038051  
714-544-2934